This post was originally published on this site The European Commission has approved two combination therapies based on Celgene‘s Revlimid (lenalidomide) and Imnovid (pomalidomide), added to Velcade (bortezomib) and dexamethasone, for the treatment of some adult patients with multiple myeloma. Revlimid, combined with Velcade and dexamethasone (RVd), is now indicated for the treatment of newly diagnosed, untreated adults…
This post was originally published on this site The U.S. Food and Drug Administration (FDA) has approved the double combination therapy of Venclexta (venetoclax) and Gazyva (obinutuzumab) for the treatment of adults with newly diagnosed chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Venclexta is a potent selective inhibitor of the B-cell lymphoma-2 (BCL-2)…
This post was originally published on this site iTeos Therapeutics’ Phase 1/1b clinical trial testing its experimental A2A receptor antagonist, EOS100850, has dosed the first group of patients with advanced solid tumors, the company announced. “I am tremendously excited to announce that patient dosing in our innovative, adaptive Phase 1/1b trial is now underway with…
This post was originally published on this site Elenbecestat and BAN2401, two potential anti-amyloid therapies, were selected by the Alzheimer’s Clinical Trials Consortium (ACTC) to be evaluated in clinical studies aiming to prevent progression to early stages of Alzheimer’s disease. ACTC is a network of 35 primary clinical trial sites across the U.S., established by the…
This post was originally published on this site Treating chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC) patients with Xtandi (enzalutamide) leads to better survival outcomes and lower healthcare costs than Zytiga (abiraterone acetate), a study suggests. The findings were presented at the American Urological Association’s 2019 Annual Meeting, May 3-6, in Chicago, in the study, “Survival…
This post was originally published on this site Takeda Oncology has launched a mentorship program aimed at empowering and encouraging multiple myeloma patients and caregivers throughout their disease journey. Called My Mentor Connections, the program enlists caregivers and patients as mentors who volunteer to provide answers and support over the phone to other patients or…
This post was originally published on this site With 250 rare diseases newly identified every year, scientists can barely keep up — even as the healthcare system fails millions of Americans whose rare diseases have already been diagnosed. That’s the warning from Christopher P. Austin, MD, director of the National Center for Advancing Translational Studies(NCATS)…
This post was originally published on this site Trastuzumab deruxtecan (DS-8201), an investigational antibody-drug conjugate developed by AstraZeneca with Daiicho Sankyo, led to clinically meaningful responses in patients with advanced HER2-positive breast cancer, a Phase 2 clinical trial shows. Trastuzumab deruxtecan is a combination of the anti-cancer HER2-targeting antibody trastuzumab (marketed under the brand name Herceptin), and an…
This post was originally published on this site High blood levels of primary fatty acid amides (PFAMS), a class of fatty molecules involved in sleep and movement control, are associated with increased accumulation of beta-amyloid protein in the cerebrospinal fluid of patients with Alzheimer’s disease, a study finds. Researchers believe that this class of fatty…
This post was originally published on this site Health Canada has approved Seattle Genetics‘ submission requesting approval of Adcetris (brentuximab vedotin) in combination with standard chemotherapy as a frontline treatment for patients with advanced (stage IV) classical Hodgkin’s lymphoma. This approval — which makes the regimen accessible to physicians and eligible patients in Canada — was…
